Lab
Luminis Health Anne Arundel Medical Center, INC.
Luminis Health Anne Arundel Medical Center, INC. was paid $5.63M by Medicaid between Jan 2018 and Dec 2024, across 135 billing codes. Its largest line is U0004, 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r — 11% of everything it billed.
33Billing provider infoLUMINIS HEALTH ANNE ARUNDEL MEDICAL CENTER, INC.
ANNAPOLIS, MD 21401
ANNAPOLIS, MD 21401
33aNPI1356885032assigned 12/14/2016
33bProvider typeClinical Medical Laboratory
28Total paid$5.63M
24GClaims517,795
24DCodes billed135
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Maryland
Rank by total paid#14 of 93
Median peer was paid$430K
This provider vs. median13×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 322 | $894.09 | |
| 2019 | 319 | $349.85 | |
| 2020 | 62,184 | $793K | |
| 2021 | 94,483 | $1.29M | |
| 2022 | 120,289 | $1.40M | |
| 2023 | 121,705 | $1.09M | |
| 2024incomplete | 118,493 | $1.05M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 11% | 9,712 | 8,445 | $604K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 7.8% | 18,790 | 15,832 | $439K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 7.8% | 18,784 | 15,836 | $438K |
| 87481 | 4.1% | 13,246 | 7,408 | $230K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 3.6% | 11,662 | 9,649 | $203K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 3.3% | 11,879 | 10,161 | $188K |
| 80053 | Comprehensive metabolic panel | 3.2% | 29,182 | 25,686 | $179K |
| 84443 | Thyroid stimulating hormone (TSH) | 3.1% | 20,918 | 18,505 | $177K |
| 80061 | Lipid panel | 2.9% | 20,044 | 18,187 | $164K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 2.9% | 6,763 | 5,877 | $162K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 2.7% | 8,926 | 7,281 | $154K |
| 87799 | 2.6% | 6,580 | 3,856 | $145K |
123 more codes
| 36415 | Collection of venous blood by venipuncture | 2.4% | 51,188 | $136K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 2.4% | 1,178 | $133K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2.3% | 8,902 | $127K |
| 86780 | 2.2% | 14,275 | $124K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 2.1% | 8,677 | $120K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.0% | 24,565 | $111K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 1.8% | 3,093 | $103K |
| 83036 | Hemoglobin; glycosylated (A1C) | 1.7% | 17,389 | $96K |
| 86803 | 1.5% | 9,451 | $86K | |
| 87512 | 1.5% | 5,261 | $84K | |
| 87653 | 1.5% | 3,255 | $82K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 1.4% | 6,304 | $80K |
| 81513 | 1.2% | 3,481 | $69K | |
| 85027 | 1.1% | 14,725 | $64K | |
| 87340 | 1.1% | 8,926 | $61K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.1% | 11,236 | $59K |
| 84702 | <1% | 4,594 | $46K | |
| 86762 | <1% | 4,635 | $44K | |
| 82728 | <1% | 5,340 | $42K | |
| 82607 | <1% | 4,232 | $34K | |
| 86850 | <1% | 4,892 | $31K | |
| 84439 | <1% | 5,401 | $31K | |
| 86480 | <1% | 782 | $30K | |
| 84153 | <1% | 2,398 | $25K | |
| 81001 | <1% | 11,375 | $25K | |
| 84466 | <1% | 3,605 | $24K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,320 | $24K |
| 83021 | <1% | 1,914 | $24K | |
| 82105 | <1% | 1,961 | $22K | |
| 86706 | <1% | 2,952 | $21K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 846 | $20K |
| 83540 | <1% | 5,359 | $20K | |
| 87077 | <1% | 3,899 | $19K | |
| 84403 | <1% | 1,250 | $18K | |
| 82043 | <1% | 4,803 | $18K | |
| 83001 | <1% | 1,374 | $17K | |
| 82746 | <1% | 2,819 | $17K | |
| 82570 | <1% | 4,883 | $16K | |
| 87088 | <1% | 3,157 | $16K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 431 | $16K |
| 87660 | <1% | 1,047 | $15K | |
| 87480 | <1% | 1,050 | $15K | |
| 87510 | <1% | 1,049 | $14K | |
| 84146 | <1% | 1,062 | $14K | |
| 84402 | <1% | 1,094 | $14K | |
| 88142 | <1% | 1,035 | $14K | |
| 83002 | <1% | 1,072 | $13K | |
| 82670 | <1% | 758 | $13K | |
| 87186 | <1% | 2,430 | $13K | |
| 82947 | <1% | 4,635 | $12K | |
| 86696 | <1% | 1,044 | $12K | |
| 88342 | <1% | 280 | $12K | |
| 84481 | <1% | 1,076 | $12K | |
| 86704 | <1% | 1,399 | $11K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 74 | $11K |
| 80050 | General health panel | <1% | 1,911 | $10K |
| 86900 | <1% | 4,853 | $10K | |
| 86901 | <1% | 4,847 | $10K | |
| 83550 | <1% | 1,554 | $9K | |
| 87563 | <1% | 325 | $9K | |
| 86376 | <1% | 835 | $8K | |
| 86038 | <1% | 1,079 | $8K | |
| 84550 | <1% | 2,245 | $7K | |
| 87625 | <1% | 213 | $6K | |
| 82784 | <1% | 552 | $6K | |
| 82951 | <1% | 619 | $6K | |
| 83735 | <1% | 1,716 | $6K | |
| 84480 | <1% | 614 | $5K | |
| 82248 | <1% | 1,590 | $5K | |
| 86708 | <1% | 582 | $5K | |
| 86140 | <1% | 1,500 | $5K | |
| 83970 | <1% | 183 | $5K | |
| 84134 | <1% | 575 | $5K | |
| 85730 | <1% | 1,429 | $5K | |
| 84425 | <1% | 629 | $5K | |
| 84163 | <1% | 354 | $4K | |
| 85610 | <1% | 1,622 | $4K | |
| 84156 | <1% | 1,577 | $4K | |
| 86787 | <1% | 505 | $4K | |
| 83013 | <1% | 73 | $3K | |
| 84436 | <1% | 733 | $3K | |
| 85652 | <1% | 1,830 | $3K | |
| 83690 | <1% | 573 | $3K | |
| 86695 | <1% | 342 | $3K | |
| 84144 | <1% | 193 | $3K | |
| 84207 | <1% | 309 | $3K | |
| 86709 | <1% | 370 | $3K | |
| 87081 | <1% | 513 | $2K | |
| 84590 | <1% | 576 | $2K | |
| 80076 | <1% | 383 | $2K | |
| 83721 | <1% | 281 | $2K | |
| 87522 | Neg quan hep c or qual rna | <1% | 69 | $2K |
| 82652 | <1% | 81 | $2K | |
| 86618 | <1% | 174 | $2K | |
| 87350 | <1% | 192 | $2K | |
| 86707 | <1% | 188 | $2K | |
| 82952 | <1% | 581 | $2K | |
| 87486 | <1% | 74 | $2K | |
| 87581 | <1% | 74 | $2K | |
| 83516 | <1% | 243 | $2K | |
| 82677 | <1% | 89 | $2K | |
| 84460 | <1% | 434 | $1K | |
| 87070 | <1% | 259 | $1K | |
| 84450 | <1% | 405 | $1K | |
| 80349 | <1% | 502 | $1K | |
| 86431 | <1% | 355 | $1K | |
| 82950 | <1% | 312 | $1K | |
| 86336 | <1% | 90 | $1K | |
| 84100 | <1% | 277 | $864.38 | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 16 | $853.39 |
| 84479 | <1% | 146 | $579.76 | |
| 83520 | <1% | 28 | $475.59 | |
| 82274 | <1% | 41 | $466.06 | |
| 83655 | <1% | 47 | $426.08 | |
| 88141 | <1% | 18 | $424.90 | |
| 86769 | <1% | 13 | $412.87 | |
| 86592 | <1% | 89 | $258.30 | |
| 83615 | <1% | 60 | $231.70 | |
| 87205 | <1% | 85 | $224.37 | |
| 82627 | <1% | 12 | $220.13 | |
| 82533 | <1% | 12 | $146.01 | |
| 82977 | <1% | 12 | $64.41 | |
| 85045 | <1% | 13 | $31.27 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialYURKON, CATHERINE (VICE PRESIDENT OF FINANCE)
Parent organizationLUMINIS HEALTH ANNE ARUNDEL MEDICAL CENTER, INC.
| Provider | Location | Paid |
|---|---|---|
| Luminis Health Pathways, INC. | Annapolis, MD | $14.40M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.